HF Foods Group Inc. to Participate in March Investor Conferences
March 17-18, 2025: The HF Foods executive management team will host a fireside chat and meetings with investors at the 37th Annual Roth Conference in Dana Point, CA. The fireside chat is scheduled to begin at 8:00 a.m. PT on Tuesday, March 18, 2025.
March 19, 2025: The HF Foods executive management team will be participating virtually in the Sidoti Small-Cap Conference. The Company will host virtual meetings with investors throughout the day.
The fireside chat at the Roth Conference will be webcast live and made available through the 'Events' section of the Company's Investor Relations website at https://investors.hffoodsgroup.com. The webcast will be archived and available for replay.
About HF Foods Group Inc.HF Foods Group Inc. is a leading marketer and distributor of fresh produce, frozen and dry food, and non-food products to primarily Asian restaurants and other foodservice customers throughout the United States. HF Foods aims to supply the increasing demand for Asian American restaurant cuisine, leveraging its nationwide network of distribution centers and its strong relations with growers and suppliers of fresh, high-quality specialty restaurant food products and supplies in the US, South America, and Asia. Headquartered in Las Vegas, Nevada, HF Foods trades on Nasdaq under the symbol 'HFFG'. For more information, please visit www.hffoodsgroup.com.
Contact:ICRInvestors: Anna Kate HellerMedia: Keil Deckerhffoodsgroup@icrinc.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Here's Third Avenue Small-Cap Value Fund's Update on Supernus Pharmaceuticals (SUPN)
Third Avenue Management, an investment management company based in New York City, released its 'Third Avenue Small-Cap Value Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 6.53% compared to -4.74% for the MSCI USA Small-Cap Value Index (the 'Index') and 4.96% return for the Russell 2000 Value Index. For more information on the fund's top picks in 2025, please check its top five holdings. In its second-quarter 2025 investor letter, Third Avenue Small-Cap Value Fund highlighted stocks such as Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company. The one-month return of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was 21.41%, and its shares gained 27.29% of their value over the last 52 weeks. On August 8, 2025, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stock closed at $41.23 per share, with a market capitalization of $2.312 billion. Third Avenue Small-Cap Value Fund stated the following regarding Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in its second quarter 2025 investor letter: "Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced an opportunistic acquisition of Sage Therapeutics, which will be funded by Supernus' $460 million net cash balance. Sage is a company which makes the first and only F.D.A. approved treatment for postpartum depression and, itself, possesses net cash in excess of $420 million as of its most recent filing." A lab technician analyzing a sample in a laboratory, showing the rigorous research conducted by the biopharmaceutical company. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 26 hedge fund portfolios held Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) at the end of the first quarter, which was 27 in the previous quarter. While we acknowledge the potential of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and shared the list of best pharma stocks to buy for long term growth. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
a minute ago
- Yahoo
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit Investor Contact Tina Ventura, IR@ Media ContactChristopher Frates, media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Rackspace Technology (RXT) Announces Launch of Rackspace Cloud Management Platform
Rackspace Technology, Inc. (NASDAQ:RXT) is one of the Best Cloud Computing Stocks to Invest in Now. On August 5, the company announced the launch of the Rackspace Cloud Management Platform, which includes next-gen upgrades to the Rackspace Managed Cloud (RMC) offering. The platform offers customers a single framework that tends to leverage best-in-class AI-enabled tools, bolstering companies to streamline workload operations, ramp up digital transformation, and more efficiently manage modern hybrid and multicloud environments. A futuristic multi-server data center, symbolizing the advanced multicloud services. Rackspace Technology, Inc. (NASDAQ:RXT) stated that go‑to‑market execution throughout both business units was strong in Q2 2025, demonstrating progress in its turnaround. Bookings saw an increase of 16%, with operating profit increasing 34% YoY. Also, Rackspace Technology, Inc. (NASDAQ:RXT) delivered positive operating cash flow. In Q2 2025, its cash flow from operating activities came in at $8 million. For Q3 2025, Rackspace Technology, Inc. (NASDAQ:RXT) expects total revenue in the range of $660 million – $674 million, with private cloud revenue of between $246 million – $254 million and public cloud revenue of $414 million – $420 million. Rackspace Technology, Inc. (NASDAQ:RXT) operates as a cloud and AI solutions company. While we acknowledge the potential of RXT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
